British American Tobacco Industries p.l.c. Common Stock ADR (BTI)
BTI trades on NYSE in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1303523/000130352326000017/0001303523-26-000017-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from GBP at 0.7561 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | BTI on NYSE |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United Kingdom |
| IPO year | 1998 |
| SEC CIK | 0001303523 |
| SEC industry code | Cigarettes |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $33.9B |
| Net income | $10.3B |
| Operating income | $13.2B |
| Net margin | 30.3% |
| Operating margin | 39.0% |
| Revenue growth | -1.0% |
| Cash | $5.1B |
| Total assets | $144.6B |
| P/E (computed) | 13.1× |
| P/S (computed) | 4.0× |
Reported in GBP; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-13 |
| Cash and burn | 3.8B GBP cash; operating cash flow 1.6B GBP a quarter. | Report 2025-12-31 |
| Shares outstanding | 2,312,454,501 (2025-12-31); 2,346,057,419 a year earlier; 2,456,867,420 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-09-08 |
| Auditor | KPMG LLP, London, United Kingdom | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 25.6B GBP | 7.8B GBP | 6.3B GBP | 3.8B GBP | 35.1B GBP | 25.6B GBP | 20-F 2026-02-13 |
| FY 2024 2024-12-31 | 25.9B GBP | 3.1B GBP | 10.1B GBP | 5.3B GBP | 37.0B GBP | 25.9B GBP | 20-F 2026-02-13 |
| FY 2023 2023-12-31 | 27.3B GBP | -14.4B GBP | 10.7B GBP | 4.7B GBP | 39.7B GBP | 27.3B GBP | 20-F 2026-02-13 |
| FY 2022 2022-12-31 | 27.7B GBP | 6.7B GBP | 10.4B GBP | 3.4B GBP | 43.1B GBP | 27.7B GBP | 20-F 2025-02-14 |
| FY 2021 2021-12-31 | 25.7B GBP | 6.8B GBP | 9.7B GBP | 2.8B GBP | 39.7B GBP | 25.7B GBP | 20-F 2024-02-09 |
| FY 2020 2020-12-31 | 25.8B GBP | 6.4B GBP | 9.8B GBP | 3.1B GBP | 44.0B GBP | 25.8B GBP | 20-F 2023-03-02 |
| FY 2019 2019-12-31 | 25.9B GBP | 5.7B GBP | 9.0B GBP | 2.5B GBP | 45.4B GBP | 25.9B GBP | 20-F 2022-03-08 |
| FY 2018 2018-12-31 | 24.5B GBP | 6.0B GBP | 10.3B GBP | 2.6B GBP | 47.5B GBP | 24.5B GBP | 20-F 2021-03-09 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in GBP.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-08-04 |
| Latest annual report | 20-F | 2026-02-13 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.6% |
| 1 month | +11.2% |
| 3 months | +7.9% |
| Year to date | +9.3% |
| 1 year | +13.6% |
| From 52-week high | -7.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MO | Altria Group Inc. | $78.90 | +0.33% | $131.2B |
| PM | Philip Morris International Inc | $196.04 | -1.47% | $305.6B |
| DFTX | Definium Therapeutics Inc. Common Shares | $30.16 | -5.99% | $4.1B |
| RGC | Regencell Bioscience Holdings Limited | $4.72 | -4.45% | $2.3B |
| TRLV | Trulieve Cannabis Corp. Subordinate Voting Shares | $10.33 | -5.23% | $2.0B |
| RLX | RLX Technology Inc. | $1.53 | -1.92% | $1.9B |
| CRON | Cronos Group Inc. Common Share | $3.27 | -3.25% | $1.2B |
| OBIO | Orchestra BioMed Holdings Inc. | $7.12 | -1.79% | $560.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier